Clinical trials: Primary Sjögren's Syndrome (pSS), active
Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA)
A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and efficacy of QLS2416 injection in participants with autoimmune diseases (AID).
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA), Primary Sjögren's Syndrome (pSS), Systemic Sclerosis (SSc)
- Trial name
- NCT07906145
- Testing
- QLS2416 Injection
- Volunteers
- 76 people
- Sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Primary Sjögren's Syndrome (pSS)
JH013 Injection in Patients With Primary Sjögren's Syndrome
This is a multicenter, open-label, single-arm Phase I study consisting of two parts: Part A, a single-dose dose-escalation phase, and Part B, a multiple-dose dose-escalation phase.
- Trial name
- NCT07818694
- Testing
- JH013 injection
- Volunteers
- 54 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Primary Sjögren's Syndrome (pSS)
Diagnostic Suspicion of Primitive Syndrome Sjögren's : Brest Cohort
This study aims to evaluate the diagnosis performance of several item used for the classification, the diagnosis and the prognostic of pSS (primary Sjogren syndrome)
- Trial name
- DIApSS (NCT03681964)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Brest
Primary Sjögren's Syndrome
The ASSESS National Multi-center Prospective Cohort
The ASSESS national multi-center prospective cohort (Assessment of Systemic complications (Signs) and Evolution in Sjögren's Syndrome "SS") was set up in 2006 thanks to a grant of the French Ministry of Health.
- Trial name
- ASSESS (NCT03040583)
- Testing
- No intervention
- Where
- France
- Volunteers
- 395 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases
This study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants…
- Trial name
- NCT07751315
- Testing
- Ia:QLS2404 very low dose, Ia:QLS2404 low dose, Ia:QLS2404 middle dose
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Primary Sjögren's Syndrome (pSS)
CM336 for Active Sjogren's Syndrome Study
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CM336 in adult participants with active primary Sjogren's Syndrome.
- Trial name
- NCT07642843
- Testing
- CM336
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Keymed Biosciences Co.Ltd
Primary Sjögren's Syndrome (pSS)
Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome
This study is designed to explore the efficacy and safety of upadacitinib and clarify the influence on immune function in the treatment of primary Sjögren's Syndrome.
- Trial name
- NCT06862284
- Testing
- Upadacitinib (ABT-494), Hydroxychloroquine (HCQ)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Primary Sjögren's Syndrome (pSS)
A Study of Yiqi Yangyin Formula in the Treatment of Primary Sjogren's Syndrome
This project aims to conduct a prospective, randomized, double-blind, controlled clinical study to clarify the efficacy and safety of the YiQi YangYin Formula in treating patients with primary Sjogren's syndrome (pSS) presenting…
- Trial name
- NCT07145060
- Testing
- Yiqi Yangyin Formula
- Where
- China
- Volunteers
- 105 people
- Sponsor
- China-Japan Friendship Hospital
Primary Sjögren's Syndrome (pSS)
Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome
The goal of this clinical trial is to learn if blinatumomab works to treat moderate-to-severe primary Sjögren's Syndrome. It will also learn about the safety of low-dose blinatumomab.
- Trial name
- NCT07852234
- Testing
- Blinatumomab, background treatment
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tongren Hospital